Editas Medicine (EDIT) Income towards Parent Company (2015 - 2025)

Editas Medicine (EDIT) has reported Income towards Parent Company for 11 consecutive years, with -$25.1 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Income towards Parent Company rose 59.58% year-over-year to -$25.1 million; the TTM figure through Dec 2025 stood at -$155.9 million (up 35.34% YoY), while the FY2024 annual figure was -$626.1 million, down 30.37% from the prior year.
• Income towards Parent Company rose to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$52.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$22.2 million in Q4 2023 and bottomed at -$4.0 billion in Q1 2022.
• Historically, Income towards Parent Company has averaged -$444.1 million across 5 years, with a median of -$67.6 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company sank 3901.13% — and 2023, when it soared 92.91%.
• Editas Medicine's Income towards Parent Company stood at -$33.7 million in 2021, then sank by 71.62% to -$57.9 million in 2022, then soared by 61.66% to -$22.2 million in 2023, then sank by 105.52% to -$45.6 million in 2024, then surged by 44.92% to -$25.1 million in 2025.
• Business Quant data shows EDIT's Income towards Parent Company at -$25.1 million in Q3 2025, -$52.0 million in Q2 2025, and -$78.9 million in Q1 2025.